Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Inclusion Criteria

• Major inclusion criteria Diagnosis/Trial Population - Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): - history of diagnosis of CLL or SLL that meets IWCLL diagnostic criteria - histologically confirmed diagnosis of SLL by lymph node biopsy - indication for treatment as defined by the IWCLL guidelines - Patients must have both of the following: - relapsed or refractory disease while receiving a BTKi therapy or intolerance of such therapy - single-agent or combination therapy with a BTKi for at least one month must be the patient's most recent prior anticancer therapy - ECOG performance status of 0 to 2 - Patients with a past medical history of autologous or allogeneic stem cell transplantation must exhibit full hematological recovery Laboratory Values • Patients must meet adequate bone marrow function and adequate hepatic and renal function Other Inclusion Criteria • Females of childbearing potential must use a highly effective method of contraception Major exclusion criteria Diagnosis • Patients who have: - non-Hodgkin's lymphomas other than CLL/SLL - transformed CLL/SLL or Richter's syndrome - active and uncontrolled autoimmune cytopenia Previous and Current Treatment - Patients who have received treatment with a BTK inhibitor within 5 days prior to Day 1 dosing - Patients who have, within 14 days prior to D1 dosing: - not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapy - systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day with the exception of patients with signs of rapidly progressing disease - received live vaccines with the exception of vaccination against influenza with inactivated virus or for pneumococcal diseases